SG Americas Securities LLC Takes $99,000 Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

SG Americas Securities LLC purchased a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA) in the 4th quarter, HoldingsChannel reports. The firm purchased 24,370 shares of the company’s stock, valued at approximately $99,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Point72 Middle East FZE purchased a new position in shares of Sana Biotechnology in the 4th quarter valued at about $37,000. Jump Financial LLC purchased a new position in shares of Sana Biotechnology in the 3rd quarter valued at about $52,000. American Century Companies Inc. increased its stake in shares of Sana Biotechnology by 72.1% in the 1st quarter. American Century Companies Inc. now owns 18,465 shares of the company’s stock valued at $57,000 after purchasing an additional 7,734 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Sana Biotechnology by 74.5% in the 2nd quarter. Royal Bank of Canada now owns 9,737 shares of the company’s stock valued at $58,000 after purchasing an additional 4,157 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Sana Biotechnology by 150.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,043 shares of the company’s stock valued at $72,000 after purchasing an additional 7,228 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $7.61 on Friday. The business has a 50 day simple moving average of $8.97 and a two-hundred day simple moving average of $5.95. Sana Biotechnology, Inc. has a 12 month low of $2.74 and a 12 month high of $12.00. The stock has a market capitalization of $1.68 billion, a P/E ratio of -5.18 and a beta of 1.61.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.03. During the same period last year, the firm posted ($0.40) earnings per share. As a group, research analysts anticipate that Sana Biotechnology, Inc. will post -1.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SANA has been the subject of a number of research analyst reports. JMP Securities increased their target price on Sana Biotechnology from $8.00 to $15.00 and gave the company a “market outperform” rating in a report on Friday, March 1st. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Sana Biotechnology in a report on Friday, March 1st.

Insider Activity at Sana Biotechnology

In related news, Director Robert Nelsen purchased 1,818,181 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average price of $5.50 per share, with a total value of $9,999,995.50. Following the completion of the acquisition, the director now owns 12,446,022 shares in the company, valued at $68,453,121. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 34.90% of the company’s stock.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.